Compare Glenmark Pharma with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs WOCKHARDT - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

WOCKHARDT 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA WOCKHARDT GLENMARK PHARMA/
WOCKHARDT
 
P/E (TTM) x 11.4 -12.1 - View Chart
P/BV x 1.6 0.9 173.9% View Chart
Dividend Yield % 0.6 0.0 15,008.5%  

Financials

 GLENMARK PHARMA   WOCKHARDT
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
WOCKHARDT
Mar-18
GLENMARK PHARMA/
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs7121,012 70.3%   
Low Rs484532 91.0%   
Sales per share (Unadj.) Rs349.6355.9 98.2%  
Earnings per share (Unadj.) Rs32.8-60.3 -54.4%  
Cash flow per share (Unadj.) Rs44.3-46.8 -94.8%  
Dividends per share (Unadj.) Rs2.000.01 20,000.0%  
Dividend yield (eoy) %0.30 25,828.3%  
Book value per share (Unadj.) Rs198.6257.8 77.1%  
Shares outstanding (eoy) m282.17110.63 255.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.72.2 78.8%   
Avg P/E ratio x18.2-12.8 -142.4%  
P/CF ratio (eoy) x13.5-16.5 -81.7%  
Price / Book Value ratio x3.03.0 100.5%  
Dividend payout %6.10 -36,775.5%   
Avg Mkt Cap Rs m168,62585,379 197.5%   
No. of employees `00012.06.3 192.5%   
Total wages/salary Rs m20,5619,371 219.4%   
Avg. sales/employee Rs Th8,196.06,295.0 130.2%   
Avg. wages/employee Rs Th1,708.11,498.3 114.0%   
Avg. net profit/employee Rs Th768.5-1,066.3 -72.1%   
INCOME DATA
Net Sales Rs m98,65539,369 250.6%  
Other income Rs m2,0811,202 173.1%   
Total revenues Rs m100,73640,571 248.3%   
Gross profit Rs m15,85818 86,656.4%  
Depreciation Rs m3,2591,495 218.0%   
Interest Rs m3,3462,555 131.0%   
Profit before tax Rs m11,335-2,830 -400.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,672-3,582 -46.7%   
Tax Rs m3,756257 1,461.6%   
Profit after tax Rs m9,250-6,669 -138.7%  
Gross profit margin %16.10 34,581.0%  
Effective tax rate %33.1-9.1 -364.9%   
Net profit margin %9.4-16.9 -55.4%  
BALANCE SHEET DATA
Current assets Rs m66,96833,796 198.2%   
Current liabilities Rs m40,21126,917 149.4%   
Net working cap to sales %27.117.5 155.2%  
Current ratio x1.71.3 132.6%  
Inventory Days Days8379 105.0%  
Debtors Days Days8189 91.0%  
Net fixed assets Rs m33,32239,664 84.0%   
Share capital Rs m282553 51.0%   
"Free" reserves Rs m55,77027,968 199.4%   
Net worth Rs m56,05228,522 196.5%   
Long term debt Rs m35,73821,731 164.5%   
Total assets Rs m132,88881,620 162.8%  
Interest coverage x4.4-0.1 -4,080.8%   
Debt to equity ratio x0.60.8 83.7%  
Sales to assets ratio x0.70.5 153.9%   
Return on assets %9.5-5.0 -188.1%  
Return on equity %16.5-23.4 -70.6%  
Return on capital %17.8-7.7 -232.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m62,9989,807 642.4%   
Fx outflow Rs m22,8591,789 1,278.0%   
Net fx Rs m40,1408,019 500.6%   
CASH FLOW
From Operations Rs m13,242684 1,934.8%  
From Investments Rs m-6,9906,302 -110.9%  
From Financial Activity Rs m-7,387-7,695 96.0%  
Net Cashflow Rs m-2,971-664 447.4%  

Share Holding

Indian Promoters % 48.3 74.5 64.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 2.3 300.0%  
FIIs % 34.4 7.7 446.8%  
ADR/GDR % 0.0 0.1 -  
Free float % 10.5 15.4 68.2%  
Shareholders   56,727 67,757 83.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   J.B.CHEMICALS  ALEMBIC LTD  WYETH LTD  AJANTA PHARMA  SUVEN LIFESCIENCES  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Economic Growth and Stock Markets: It's Not All Gloom and Doom(Podcast)

In addition to the usual stock market updates of the week, I talk about how RBI's monetary policy decision and slowing economy impacts you and your portfolio of stocks.

Related Views on News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)

May 7, 2019 | Updated on May 7, 2019

For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

More Views on News

Most Popular

Could this Smallcap Be the Next Page Industries?(Profit Hunter)

Nov 27, 2019

A single stock - Coca Cola, made Buffett billions. Here's your chance to break into the crorepati club with a single smallcap stock investment.

How We Made 12.68% in One Overnight Trade(The 5 Minute Wrapup)

Nov 25, 2019

This one trade had my subscribers laughing all the way to the bank.

Growth Stocks or Value Stocks... What Will Make You More Money in this Bull Market?(Profit Hunter)

Nov 28, 2019

Should you invest in growth stocks or value stocks to make strong returns in this market?

Two Trends to Look at as Sensex Crosses 41,000 Levels(Views On News)

Nov 26, 2019

The two trends that are playing out as Sensex touches new record high.

The Best Trading Strategy for Fast Profits

Nov 29, 2019

Vijay and I have decided to team up and bring you a unique offering never seen before in the Indian stock markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Dec 6, 2019 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS